These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 1918729)
1. Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. Bochner BS; Friedman B; Krishnaswami G; Schleimer RP; Lichtenstein LM; Kroegel C J Allergy Clin Immunol; 1991 Oct; 88(4):629-36. PubMed ID: 1918729 [TBL] [Abstract][Full Text] [Related]
2. Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. Owen WF; Petersen J; Sheff DM; Folkerth RD; Anderson RJ; Corson JM; Sheffer AL; Austen KF Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8647-51. PubMed ID: 2236076 [TBL] [Abstract][Full Text] [Related]
3. Effect of L-tryptophan products on function of human eosinophils: investigation of the causal mechanisms of eosinophilia myalgia syndrome associated with L-tryptophan products. Saito H; Miyamoto T Int Arch Allergy Immunol; 1996; 111 Suppl 1():37-42. PubMed ID: 8906111 [TBL] [Abstract][Full Text] [Related]
4. Eosinophil-active cytokine from mononuclear cells cultured with L-tryptophan products: an unexpected consequence of endotoxin contamination. Kita H; Mayeno AN; Weyand CM; Goronzy JJ; Weiler DA; Lundy SK; Abrams JS; Gleich GJ J Allergy Clin Immunol; 1995 Jun; 95(6):1261-7. PubMed ID: 7797795 [TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production. Macdonald D; Gordon AA; Kajitani H; Enokihara H; Barrett AJ Br J Haematol; 1990 Oct; 76(2):168-73. PubMed ID: 2094320 [TBL] [Abstract][Full Text] [Related]
6. The effects of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 on the secretory capacity of human blood eosinophils. Tai PC; Spry CJ Clin Exp Immunol; 1990 Jun; 80(3):426-34. PubMed ID: 2197048 [TBL] [Abstract][Full Text] [Related]
7. Pathways for eosinophil lipid body induction: differing signal transduction in cells from normal and hypereosinophilic subjects. Bozza PT; Yu W; Cassara J; Weller PF J Leukoc Biol; 1998 Oct; 64(4):563-9. PubMed ID: 9766638 [TBL] [Abstract][Full Text] [Related]
9. Comparison of platelet-activating factor-induced chemotaxis of normodense and hypodense eosinophils. Little MM; Casale TB J Allergy Clin Immunol; 1991 Aug; 88(2):187-92. PubMed ID: 1880319 [TBL] [Abstract][Full Text] [Related]
10. GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor. Tomioka K; MacGlashan DW; Lichtenstein LM; Bochner BS; Schleimer RP J Immunol; 1993 Nov; 151(9):4989-97. PubMed ID: 8409452 [TBL] [Abstract][Full Text] [Related]
11. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Varga J; Uitto J; Jimenez SA Ann Intern Med; 1992 Jan; 116(2):140-7. PubMed ID: 1727618 [TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of IL-5, GM-CSF, and IL-3 and the production by lymphocytes in various eosinophilia. Koike T; Enokihara H; Arimura H; Ninomiya H; Yamashiro K; Tsuruoka N; Tsujimoto M; Aoyagi M; Watanabe K; Nakamura Y Am J Hematol; 1995 Oct; 50(2):98-102. PubMed ID: 7573007 [TBL] [Abstract][Full Text] [Related]
13. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. Owen WF; Rothenberg ME; Silberstein DS; Gasson JC; Stevens RL; Austen KF; Soberman RJ J Exp Med; 1987 Jul; 166(1):129-41. PubMed ID: 3110347 [TBL] [Abstract][Full Text] [Related]
15. Elevated L-kynurenine level and its normalization by prednisolone in a patient with eosinophilia-myalgia syndrome. Hisatomi A; Kubota A; Ohashi M; Umeda F; Nawata H; Imamura T; Nagata T Fukuoka Igaku Zasshi; 1997 Jan; 88(1):11-7. PubMed ID: 9037890 [TBL] [Abstract][Full Text] [Related]
16. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Butterfield JH; Leiferman KM; Abrams J; Silver JE; Bower J; Gonchoroff N; Gleich GJ Blood; 1992 Feb; 79(3):688-92. PubMed ID: 1732010 [TBL] [Abstract][Full Text] [Related]
17. Granulocyte/macrophage-colony stimulating factor in allergen-induced rhinitis: cellular localization, relation to tissue eosinophilia and influence of topical corticosteroid. Nouri-Aria KT; Masuyama K; Jacobson MR; Rak S; Lowhagen O; Schotman E; Hamid Q; Durham S Int Arch Allergy Immunol; 1998 Dec; 117(4):248-54. PubMed ID: 9876226 [TBL] [Abstract][Full Text] [Related]
18. CD11b/CD18 (Mac-1) is required for degranulation of human eosinophils induced by human recombinant granulocyte-macrophage colony-stimulating factor and platelet-activating factor. Horie S; Kita H J Immunol; 1994 Jun; 152(11):5457-67. PubMed ID: 7514638 [TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5. Yamaguchi T; Kimura H; Kurabayashi M; Kozawa K; Kato M Immunol Lett; 2008 Jun; 118(1):88-95. PubMed ID: 18440651 [TBL] [Abstract][Full Text] [Related]